Screener
Relmada Therapeutics, Inc. RLMD Restricted stock acquisition consideration
Restricted stock acquisition consideration at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross.
The source filing: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-055059
| Line item | Common Stock / Shares | Common Stock / Par Value | Additional Paid-in / Capital | Accumulated / Deficit | Total |
|---|---|---|---|---|---|
| Balance - December 31, 2024 | 30,174,202 | $30,174 | $676,373,822 | $(640,882,035) | $35,521,961 |
| Stock based compensation | - | - | 3,572,769 | - | 3,572,769 |
| Issuance of restricted common stock | 3,017,420 | 3,017 | 902,209 | - | 905,226 |
| Net loss | - | - | - | (17,559,465) | (17,559,465) |
| Balance – March 31, 2025 | 33,191,622 | $33,191 | $680,848,800 | $(658,441,500) | $22,440,491 |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Relmada Therapeutics, Inc.'s restricted stock acquisition consideration?
- Relmada Therapeutics, Inc. (RLMD) reported restricted stock acquisition consideration of $905.23K in Q1 2025.
- What does restricted stock acquisition consideration mean?
- The gross value of restricted stock awards granted to employees or directors during the period. This metric highlights the company's reliance on restricted equity as a primary tool for talent retention and long-term incentive alignment.
Ask your AI about Relmada Therapeutics, Inc.'s restricted stock acquisition consideration.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude